Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform — with billions on the line
A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally itself with the upstart …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
